February 01, 2018 -- Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on Agenus Inc. (NASDAQ: AGEN), Antares Pharma, Inc. (NASDAQ: ATRS), Senseonics Holdings, Inc. (NYSE: SENS), Abraxas Petroleum Corporation (NASDAQ: AXAS) and or latest research report and comprehensive study on two of the hottest sectors in the market.
 
Agenus Inc. (NASDAQ: AGEN), a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer and develops vaccine programs, such as the Prophage cancer vaccine. Recently they announced the launch of its Phase 1/2 clinical combination trial with its proprietary anti-CTLA4 (AGEN1884) and anti-PD1 (AGEN2034) antibodies. This two-part trial is designed to evaluate the safety, tolerability, pharmacokinetics of the dual drug combination in patients with advanced solid tumors.
 
Read our latest comprehensive report on the most promising Blockchain & Cannabis stocks READ MORE
Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/mmj-blockchain-report/
 
Antares Pharma, Inc. (NASDAQ: ATRS), is developing a new drug, XYOSTED, for the treatment of testosterone deficiency. They recently announced that a “Type A” meeting has been scheduled with the U.S. Food and Drug Administration (FDA) on February 21, 2018 for XYOSTED due to the “Complete Response Letter” received regarding the New Drug Application for XYOSTED. Antares Pharma, Inc. is also working with AMAG Pharmaceuticals on a method for administering Makena, a product indicated for use in lowering the risk of pre-term birth.


Senseonics Holdings, Inc. (NYSE: SENS), a medical technology company focused on the development of Eversense, a long-term, implantable continuous glucose monitoring system for people with diabetes for a period of up to 90 days. The company has not received FDA approval yet but is already selling in Europe. In the U.S. alone, nearly 7 million patients are on insulin but only a small portion use this kind of therapy and the consensus Wall Street one-year target is 55% over the current stock price if they get the anticipated FDA approval.
 
Get our latest research on some of the most unique Cannabis and Blockchain stocks READ MORE
Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/mmj-blockchain-report/
 
 
Abraxas Petroleum Corporation (NASDAQ: AXAS), is an independent energy company that engages in the acquisition, development, and production of oil and gas properties in the United States and operates assets in the Permian/Delaware Basin, the Rocky Mountain, and South Texas regions. They recently announced that seven wells located in Delaware Basin, Bakken/Three Forks and Eagle Ford are completed and in full production and will be producing to targeted expectations. Also with recent acquisitions and additional identified opportunities at their Bone Spring/Wolfcamp will allow Abraxas to achieve their goal of over 10,000 net acres. With this latest information Abraxas believes it will now drill and complete 12 gross and nine operated wells in 2018 instead of their previous assumption or 10 gross and seven net wells.
 
 
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the subject company in this report to be materially different from the statements made herein.


COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. Information in this release is fact checked and produced on a best efforts basis. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. The subject Company has not compensated Traders News Source for the creation or dissemination of this report. Traders News Source is the party responsible for issuing the press release and for hosting the full analyst report on Traders News Source website.


NOT FINANCIAL ADVICE
Traders News Source makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


NO WARRANTY OR LIABILITY ASSUMED
Traders News Source is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Traders News Source whatsoever for any direct, indirect or consequential loss arising from the use of this document. Traders News Source expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Traders News Source does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


Source: Traders News Source
Contact: editor@tradersnewssource.com

Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Agenus Charts.
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Agenus Charts.